Tim Luetkens, MD

Research Interests

  • Cancer Immunotherapy
  • Protein Engineering

Languages

  • English
  • French
  • German

Academic Information

  • Departments: Internal Medicine - Research Assistant Professor
  • Divisions: Hematology/BMT

Academic Office Information

  • 801-587-4641
  • Huntsman Cancer Institute
    2000 Circle of Hope, Room: 5261
    Salt Lake City, UT 84112

Academic Bio

Dr. Tim Luetkens is an Assistant Professor in the Division of Hematology and Hematologic Malignancies in the Department of Internal Medicine and the Huntsman Cancer Institute (HCI) at the University of Utah. His research background includes tumor antigen discovery, antibody development, and the genetic engineering of immune cells. At HCI, Dr Luetkens uses this expertise to develop targeted immunotherapies for the treatment of cancer.

Research Statement

The goal of Dr. Luetkens' research is the translational development of novel immunotherapies for the treatment of cancer. In particular, he is focusing on developing safe and effective receptor-transgenic T cells targeting antigens specifically expressed by tumor cells. He has developed high-throughput platforms for the development and screening of novel chimeric antigen receptors and monoclonal antibodies and is working on strategies to improve the manufacturing of receptor-transgenic T cells for the clinic.

Education History

Type School Degree
Postdoctoral Training University of Cambridge
Antibody engineering
Postdoctoral Training
Research Fellow University Medical Center Hamburg-Eppendorf
Tumor immunology
Research Fellow
Graduate Training Center for Molecular Neurobiology at the University of Hamburg
Molecular Biology
Graduate Diploma
Professional Medical University of Hamburg
Medicine
M.D.

Global Impact

Education History

Type School Degree Country
Postdoctoral Training University of Cambridge
Antibody engineering
Postdoctoral Training United Kingdom
Research Fellow University Medical Center Hamburg-Eppendorf
Tumor immunology
Research Fellow Germany
Graduate Training Center for Molecular Neurobiology at the University of Hamburg
Molecular Biology
Graduate Diploma Germany
Professional Medical University of Hamburg
Medicine
M.D. Germany

Selected Publications

Journal Article

  1. Atanackovic D, Luetkens T (2018). Biomarkers for checkpoint inhibition in hematologic malignancies. Semin Cancer Biol, 52(Pt 2), 198-206.
  2. Radhakrishnan SV, Bhardwaj N, Steinbach M, Weidner J, Luetkens T, Atanackovic D (2017). Elotuzumab as a novel anti-myeloma immunotherapy. Hum Vaccin Immunother, 13(8), 1751-1757.
  3. Templin J, Atanackovic D, Hasche D, Radhakrishnan SV, Luetkens T (2017). Oscillating expression of interleukin-16 in multiple myeloma is associated with proliferation, clonogenic growth, and PI3K/NFKB/MAPK activation. Oncotarget, 8(30), 49253-49263.
  4. Radhakrishnan SV, Bhardwaj N, Luetkens T, Atanackovic D (2017). Novel anti-myeloma immunotherapies targeting the SLAM family of receptors. Oncoimmunology, 6(5), e1308618.
  5. Luetkens T, Yousef S, Radhakrishnan SV, Atanackovic D (2017). Current Strategies for the Immunotherapy of Multiple Myeloma. Oncology (Williston Park), 31(1), 55-63.
  6. Atanackovic D, Luetkens T, Radhakrishnan S, Kroger N (2017). Coinhibitory Molecule PD-1 as a Therapeutic Target in the Microenvironment of Multiple Myeloma. Curr Cancer Drug Targets, 17(9), 839-845.
  7. Atanackovic D, Steinbach M, Radhakrishnan SV, Luetkens T (2016). Immunotherapies targeting CD38 in Multiple Myeloma. Oncoimmunology, 5(11), e1217374.
  8. Jordan K, Luetkens T, Gog C, Killing B, Arnold D, Hinke A, Stahl M, Freier W, Rssel J, Atanackovic D, Hegewisch-Becker S (2016). Intraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: A multicentre double-blind, placebo-controlled phase II study - AIO SUP-0108. Eur J Cancer, 63, 127-34.
  9. Atanackovic D, Radhakrishnan SV, Bhardwaj N, Luetkens T (2016). Chimeric Antigen Receptor (CAR) therapy for multiple myeloma. Br J Haematol, 172(5), 685-98.
  10. Lajmi N, Luetkens T, Yousef S, Templin J, Cao Y, Hildebrandt Y, Bartels K, Krger N, Atanackovic D (2015). Cancer-testis antigen MAGEC2 promotes proliferation and resistance to apoptosis in Multiple Myeloma. Br J Haematol, 171(5), 752-62.
  11. Yousef S, Heise J, Lajmi N, Bartels K, Krger N, Luetkens T, Atanackovic D (2015). Cancer-testis antigen SLLP1 represents a promising target for the immunotherapy of multiple myeloma. J Transl Med, 13, 197.
  12. Yousef S, Kovacsovics-Bankowski M, Salama ME, Bhardwaj N, Steinbach M, Langemo A, Kovacsovics T, Marvin J, Binder M, Panse J, Krger N, Luetkens T, Atanackovic D (2015). CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma. Hum Vaccin Immunother, 11(7), 1606-11.
  13. Luetkens T, Kobold S, Cao Y, Ristic M, Schilling G, Tams S, Bartels BM, Templin J, Bartels K, Hildebrandt Y, Yousef S, Marx A, Haag F, Bokemeyer C, Krger N, Atanackovic D (2014). Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation. Cancer Immunol Immunother, 63(11), 1151-62.
  14. Laban S, Atanackovic D, Luetkens T, Knecht R, Busch CJ, Freytag M, Spagnoli G, Ritter G, Hoffmann TK, Knuth A, Sauter G, Wilczak W, Blessmann M, Borgmann K, Muenscher A, Clauditz TS (2014). Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer. Int J Cancer, 135(5), 1142-52.
  15. Atanackovic D, Luetkens T, Krger N (2014). Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. Leukemia, 28(5), 993-1000.
  16. Stbig T, Badbaran A, Luetkens T, Hildebrandt Y, Atanackovic D, Binder TM, Fehse B, Krger N (2014). 5-azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity. Mediators Inflamm, 2014, 418292.
  17. Atanackovic D, Reinhard H, Meyer S, Spck S, Grob T, Luetkens T, Yousef S, Cao Y, Hildebrandt Y, Templin J, Bartels K, Lajmi N, Stoiber H, Krger N, Atz J, Seimetz D, Izbicki JR, Bokemeyer C (2013). The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting. Hum Vaccin Immunother, 9(12), 2533-42.
  18. Kobold S, Luetkens T, Bartels BM, Cao Y, Hildebrandt Y, Sezer O, Reinhard H, Templin J, Bartels K, Lajmi N, Haag F, Bokemeyer C, Krger N, Atanackovic D (2012). Longitudinal analysis of tetanus- and influenza-specific IgG antibodies in myeloma patients. Clin Dev Immunol, 2012, 134081.
  19. Atanackovic D, Luetkens T, Kloth B, Fuchs G, Cao Y, Hildebrandt Y, Meyer S, Bartels K, Reinhard H, Lajmi N, Hegewisch-Becker S, Schilling G, Platzbecker U, Kobbe G, Schroeder T, Bokemeyer C, Krger N (2011). Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia. Am J Hematol, 86(11), 918-22.
  20. Kobold S, Tams S, Luetkens T, Cao Y, Sezer O, Bartels BM, Reinhard H, Templin J, Bartels K, Hildebrandt Y, Lajmi N, Marx A, Haag F, Bokemeyer C, Krger N, Atanackovic D (2011). Patients with multiple myeloma develop SOX2-specific autoantibodies after allogeneic stem cell transplantation. Clin Dev Immunol, 2011, 302145.
  21. Luetkens T, Schafhausen P, Uhlich F, Stasche T, Akbulak R, Bartels BM, Hildebrandt Y, Gontarewicz A, Kobold S, Meyer S, Gordic M, Bartels K, Lajmi N, Cao Y, Krger N, Bokemeyer C, Brmmendorf TH, Atanackovic D (2010). Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia. Leuk Res, 34(12), 1647-55.
  22. Pabst C, Zustin J, Jacobsen F, Luetkens T, Krger N, Schilling G, Bokemeyer C, Sauter G, Atanackovic D, Marx A (2010). Expression and prognostic relevance of MAGE-C1/CT7 and MAGE-C2/CT10 in osteolytic lesions of patients with multiple myeloma. Exp Mol Pathol, 89(2), 175-81.
  23. Cao Y, Luetkens T, Kobold S, Hildebrandt Y, Gordic M, Lajmi N, Meyer S, Bartels K, Zander AR, Bokemeyer C, Krger N, Atanackovic D (2010). The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients. Exp Hematol, 38(10), 860-7.
  24. Gnjatic S, Cao Y, Reichelt U, Yekebas EF, Nlker C, Marx AH, Erbersdobler A, Nishikawa H, Hildebrandt Y, Bartels K, Horn C, Stahl T, Gout I, Filonenko V, Ling KL, Cerundolo V, Luetkens T, Ritter G, Friedrichs K, Leuwer R, Hegewisch-Becker S, Izbicki JR, Bokemeyer C, Old LJ, Atanackovic D (2010). NY-CO-58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancer. Int J Cancer, 127(2), 381-93.
  25. Cao Y, Gordic M, Kobold S, Lajmi N, Meyer S, Bartels K, Hildebrandt Y, Luetkens T, Ihloff AS, Krger N, Bokemeyer C, Atanackovic D (2010). An optimized assay for the enumeration of antigen-specific memory B cells in different compartments of the human body. J Immunol Methods, 358(1-2), 56-65.
  26. Freier E, Weber CS, Nowottne U, Horn C, Bartels K, Meyer S, Hildebrandt Y, Luetkens T, Cao Y, Pabst C, Muzzulini J, Schnee B, Brunner-Weinzierl MC, Marangolo M, Bokemeyer C, Deter HC, Atanackovic D (2010). Decrease of CD4(+)FOXP3(+) T regulatory cells in the peripheral blood of human subjects undergoing a mental stressor. Psychoneuroendocrinology, 35(5), 663-73.
  27. Atanackovic D, Hildebrandt Y, Jadczak A, Cao Y, Luetkens T, Meyer S, Kobold S, Bartels K, Pabst C, Lajmi N, Gordic M, Stahl T, Zander AR, Bokemeyer C, Krger N (2010). Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells. Haematologica, 95(5), 785-93.
  28. Kobold S, Luetkens T, Cao Y, Bokemeyer C, Atanackovic D (2010). Prognostic and diagnostic value of spontaneous tumor-related antibodies. Clin Dev Immunol, 2010, 721531.
  29. Atanackovic D, Luetkens T, Hildebrandt Y, Arfsten J, Bartels K, Horn C, Stahl T, Cao Y, Zander AR, Bokemeyer C, Krger N (2009). Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma. Clin Cancer Res, 15(4), 1343-52.
  30. Panse J, Friedrichs K, Marx A, Hildebrandt Y, Luetkens T, Barrels K, Horn C, Stahl T, Cao Y, Milde-Langosch K, Niendorf A, Krger N, Wenzel S, Leuwer R, Bokemeyer C, Hegewisch-Becker S, Atanackovic D (2008). Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients. Br J Cancer, 99(6), 930-8.
  31. Atanackovic D, Cao Y, Luetkens T, Panse J, Faltz C, Arfsten J, Bartels K, Wolschke C, Eiermann T, Zander AR, Fehse B, Bokemeyer C, Kroger N (2008). CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation. Haematologica, 93(3), 423-30.

Letter

  1. Atanackovic D, Yousef S, Shorter C, Tantravahi SK, Steinbach M, Iglesias F, Sborov D, Radhakrishnan SV, Chiron M, Miles R, Salama M, Krger N, Luetkens T (2019). In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab. [Letter to the editor]. Leukemia.
  2. Yousef S, Marvin J, Steinbach M, Langemo A, Kovacsovics T, Binder M, Krger N, Luetkens T, Atanackovic D (2015). Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients. [Letter to the editor]. Blood Cancer J, 5, e285.
  3. Reinhard H, Yousef S, Luetkens T, Fehse B, Berdien B, Krger N, Atanackovic D (2014). Cancer-testis antigen MAGE-C2/CT10 induces spontaneous CD4+ and CD8+ T-cell responses in multiple myeloma patients. [Letter to the editor]. Blood Cancer J, 4, e212.

Video/Film/CD/Web/Podcast

  1. Luetkens T (2012). PJ-Ranking.de - Popular website for the evaluation of the clinical education of medical students in Germany. [Web]. Available: http://www.pj-ranking.de/.

Patent

  1. Luetkens T, Iglesias F, Atanackovic D (2019). Compositions and Methods for Upregulating HLA Class I on Tumor Cells. U.S. Patent No. 62/940,689. Washington, D.C.:U.S. Patent and Trademark Office.
  2. Luetkens T, Atanackovic D, Radhakrishnan SV (2019). CD229 CAR T Cells and Methods of Use Thereof. U.S. Patent No. WO2018017708A1. Washington, D.C.:U.S. Patent and Trademark Office.
  3. Karatt Vellat A, Mccafferty J, Surade S, Luetkens T, Masters E, Dyson M (2019). Binding members with altered diversity scaffold domains. U.S. Patent No. WO2017118761A1. Washington, D.C.:U.S. Patent and Trademark Office.
  4. Karatt Vellatt A, Mccafferty J, Surade SB, Luetkens T, Masters EW, Dyson MR, Bell DC. (2019). Sodium Channel Inhibitors. U.S. Patent No. WO2019012014A1. Washington, D.C.:U.S. Patent and Trademark Office.
  5. Karatt Vellatt A, Mccafferty J, Surade SB, Luetkens T, Masters EW, Dyson MR, Bell DC. (2019). Potassium Channel Inhibitors. U.S. Patent No. WO2019012015A1. Washington, D.C.:U.S. Patent and Trademark Office.
  6. Luetkens T, Atanackovic D (2013). Diagnosis and therapy of hematological malignancies. U.S. Patent No. US8524240. Washington, D.C.:U.S. Patent and Trademark Office.